10/14/2013 8:14:34 AM
14 October 2013 -- The BioIndustry Association (BIA) appointed Kevin Cox, Donna Hackett, Jane Osbourn, Stephen Taylor, Patrick Verheyen and Tim Watts to its Board of Directors at its Annual General Meeting on 10 October 2013. In addition, John Brown and Ian Tomlinson have been re-appointed to the Board. The new and re-appointed Board members will serve from 1 January 2014 for a term of three years.
Edward Hodgkin, BIA Chairman, said:
"I am delighted to welcome our new Board members and congratulate our re-appointed Board members. The appointees are recognised leaders of our industry and I look forward to working with them to help the BIA meet the needs of the bioscience sector in Europe's strongest bioscience cluster.
"I would also like to thank Janis Clayton, Jeremy Haigh, Keith Martin, Geoff Newman and Peter Nolan who are standing down at the end of the year for their service to the BIA and its members."
Steve Bates, BIA Chief Executive Officer, said:
"It is a privilege to work with such heavyweight talent from across our sector. The BIA Board has international reputation in research and development, business development, biopharmaceutical manufacturing and finance."
For further information, please contact Robert Winder, Head of Communications, email@example.com, 020 7630 2191; mobile 07825 942 934.
New and re-appointed BIA Board members:
- John Brown, Non-executive Director, Vectura Group plc
- Kevin Cox, Chief Executive Officer, Imanova Ltd
- Donna Hackett, Director, KDH BioManagement
- Jane Osbourn, VP Research and Development Biosuperiors, MedImmune
- Stephen Taylor, Commercial Director, Fujifilm Diosynth Biotechnologies
- Ian Tomlinson, Senior Vice President and Head of Worldwide Business Development (WWBD) and
- Biopharmaceuticals R&D, GlaxoSmithKline plc
- Patrick Verheyen, Head, Johnson & Johnson Innovation, London
- Tim Watts, Chief Financial Officer, Oxford BioMedica plc
Founded over 20 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives. For further information, please go to www.bioindustry.org
Help employers find you! Check out all the jobs and post your resume.
comments powered by